Advances in the mechanism of action of nobiletin in Alzheimer's disease

WANG Fan,NI Ying,LI Weigang,CHEN Chao,ZHANG Wensheng

DOI: https://doi.org/10.3969/j.issn.1674-1749.2023.12.038

2023-01-01

Abstract:Nobiletin is derived from the polymethoxyflavonoids(PMFs)component of the traditional Chinese medicine Chen Pi,which has anti-tumour,antioxidant,anti-inflammatory,anti-obesity and anti-atherosclerotic properties,and modern research has shown it has good potential in the treatment of Alzheimer's disease(AD).AD is a neurodegenerative disease that is a serious health and social problem and is most commonly treated with drugs.It has been shown that Nobiletin exerts its effects in preventing and treating AD through various mechanisms,by inhibiting the activity of BACE1,increasing the activity of NEP,regulating cAMP/PKA/ERK and reducing Aβ neurotoxicity;increasing the activity of CHAT,reducing the activity of ACHE,increasing the phosphorylation level of GLUR1 and improving the synaptic plasticity of neurons;regulating the levels of ROS,SOD,MDA and apoptosis-related genes and reducing oxidative damage to neuronal cells;regulating the PI2K/AKT and NF-κB signaling pathways,modulating levels of inflammatory factors and reducing neuroinflammatory damage;reversing Tau hyperphosphorylation and improving microtubule cytoskeleton disorders;regulating insulin signaling and mitochondrial function and improves circadian rhythm and sleep cycle dysregulation.But there are still few clinical trials of Nobiletin for the treatment of AD,and relevant studies still need to be further strengthened to provide a pre-liminary basis for the development of new drugs for the treatment of AD.